Trials / Completed
CompletedNCT05803187
Clinical Study of Stage IV Psoriasis in Children With Geleli
A Prospective, Observaional Multi-Center Phase IV Study to Evaluate the Efficacy and Safety of QLETLI (Adalimumab Biosimilar) in Pediatric and Juvenile Subjects With Severe Plaque Psoriasis (PISCES Trials)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- Bio-Thera Solutions · Industry
- Sex
- All
- Age
- 4 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, prospective, observational phase IV clinical study. A total of 80 children and adolescents with severe plaque psoriasis were included in the study. The study is expected to last for 24 weeks (169 days). This study will evaluate the efficacy and safety of Valerie ® (Adalimumab Injection) in Chinese children over 4 years old and adolescents with severe plaque psoriasis.
Conditions
Timeline
- Start date
- 2023-04-05
- Primary completion
- 2025-03-30
- Completion
- 2025-03-30
- First posted
- 2023-04-07
- Last updated
- 2026-03-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05803187. Inclusion in this directory is not an endorsement.